Quavonlimab/Pembrolizumab Combo Shows Modest Antitumor Activity in Advanced Melanoma

Source: Onc Live, June 2022

The combination of quavonlimab (MK-1308) and pembrolizumab (Keytruda) was found to be generally well tolerated and to have modest antitumor activity in patients with advanced melanoma that progressed on a PD-1/PD-L1 inhibitor, according to data from a phase 1/2 trial (NCT03179436).

The findings, which were presented during the 2022 AACR Annual Meeting, showed that the doublet (n = 111) elicited an objective response rate (ORR) of 9.0% (95% CI, 4.4%-15.9%) per RECIST v1.1 criteria by blinded independent central review (BICR) vs 2.5% (95% CI, 0.1%-13.2%) with quavonlimab monotherapy (n = 40).

In the quavonlimab/pembrolizumab arm, the complete response rate was 0.9%, the partial response (PR) rate was 8.1%, and the stable disease (SD) rate was 28.8%); 53.2% experienced disease progression, 1.8% were not evaluable for response, and 7.2% were not assessed. In the quavonlimab monotherapy arm, 2.5% of patients achieved a PR, 35.0% had stable disease, and 57.5% experienced disease progression; 2.5% were not evaluable and 2.5% were not assessed.